25125-22-8

Upstream product

• 25125-21-7 4-(hydroxymethyl)cyclopentene 
• 98-59-9 p-toluenesulfonyl chloride 
• 7686-77-3 3-cyclopentene-1-carboxylic acid 
• 58101-60-3 methyl cyclopent-3-ene-1-carboxylate 

Downstream Products

• 195720-15-1 1-[(Cyclopent-1-en-1-yl)methyl]-5-ethyl-6-phenylthio-2,4-pyrimidinedione 
• 1245736-00-8 [3,3:7,7-bis(2,2-dimethyl-1,3-propylidenedioxy)-cis-bicyclo[3.3.0]oct-1-yl]methyl tosylate 
• 1245736-01-9 1-[(cyclopent-3-enyl)methoxymethyl]-3,3:7,7-bis-(2,2-dimethyl-1,3-propylidenedioxy)-cis-bicyclo[3.3.0]octane 
• 21727-39-9 cyclopentylmethyltrimethylammonium iodide 
• 1245736-03-1 4-[[3,3:7,7-bis(2,2-dimethyl-1,3-propylidenedioxy)-cis-bicyclo[3.3.0]oct-1-yl]methoxymethyl]-2-hydroxycyclopent-2-en-1-one 

Relevant academic research and scientific papers

Rhodium-catalyzed desymmetrization by hydroformylation of cyclopentenes: Synthesis of chiral carbocyclic nucleosides

Excellent enantioselectivities (up to 97 % ee) and diastereoselectivities (up to >99:1 d.r.) have been achieved in the desymmetrization of cyclopentenes by catalytic hydroformylation. This novel methodology provides an efficient and concise synthetic route to chiral cyclopentane carboxaldehydes. The key intermediate, (1S,3S)-(3-hydroxymethyl)cyclopentanol, for the synthesis of carbocyclic-ddA was obtained in three steps. Efficient access: A Rh/Yanphos complex catalyzed the desymmetrization of cyclopentenes through hydroformylation, thus giving cyclopentane carboxaldehydes with good yields and excellent diastereo- and enantioselectivities. This procedure provides efficient access to chiral carbocyclic nucleosides and exhibits good application prospects in organic synthesis.

HETEROARYL RHEB INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. Compositions comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of the compound in compositions of this invention is such that it is effective to measurably inhibit Rheb, in a biological sample or in a patient.